Effects of Acute and Chronic Treatments with Dopamine D₂ and D₃ Receptor Ligands on Cocaine versus Food Choice in Rats

Morgane Thomsen, Andrew C. Barrett,¹ Paul Butler, S. Stevens Negus, and S. Barak Caine

Alcohol and Drug Abuse Research Center, McLean Hospital, Belmont, Massachusetts (M.T., A.C.B., S.B.C.); Department of Psychiatry, Harvard Medical School, Belmont, Massachusetts (M.T., A.C.B., S.B.C.); Laboratory of Neuropsychiatry, Psychiatric Centre Copenhagen, University of Copenhagen, Copenhagen, Denmark (M.T.); Drug Safety Research and Development, Pfizer, San Diego, California (P.B.); and Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (S.S.N.)

Received March 5, 2017; accepted April 20, 2017

ABSTRACT

Dopamine D₃ receptor ligands are potential medications for psychostimulant addiction. Medication assessment may benefit from preclinical studies that evaluate chronic medication effects on choice between an abused drug and an alternative, nondrug reinforcer. This study compared acute and chronic effects of dopamine D₂- and D₃-preferring ligands on choice between intravenous cocaine and palatable food in rats. Under baseline conditions, cocaine maintained dose-dependent increases in cocaine choice and reciprocal decreases in food choice. Acutely, the D₂ agonist *R*-(–)-norpropylapomorphine (NPA) and antagonist L-741,626 [3-[[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]methyl-1*H*-indole] produced leftward and rightward shifts in cocaine dose-effect curves, respectively, whereas the partial agonist terguride had no effect. All three drugs dose-dependently decreased food-maintained responding. Chronically, the effects of *R*-(–)-norpropylapomorphine and L-741,626 on cocaine self-administration showed marked tolerance, whereas suppression of

food-reinforced behavior persisted. Acute effects of the D₃ ligands were less systematic and most consistent with nonselective decreases in cocaine- and food-maintained responding. Chronically, the D₃ agonist PF-592,379 [5-[(2*R*,5*S*)-5-methyl-4-propylmorpholin-2-yl]pyridin-2-amine] increased cocaine choice, whereas an intermediate dose of the D₃ antagonist PG01037 [*N*-[(*E*)-4-[4-(2,3-dichlorophenyl)piperazin-1-yl]but-2-enyl]-4-pyridin-2-ylbenzamide] produced a therapeutically desirable decrease in cocaine choice early in treatment; however, tolerance to this effect developed, and lower and higher doses were ineffective. D₃ ligands failed to significantly modify total cocaine intake but caused persistent decreases in food intake. Thus, D₂- and D₃-preferring ligands showed distinct profiles, consistent with different pharmacological actions. In addition, these results highlight the role of acute versus chronic treatment as a determinant of test drug effects. With the possible exception of the D₃ antagonist PG01037, no ligand was promising in terms of cocaine addiction treatment.

Introduction

Substance use disorders have become a problem of epidemic proportions in the United States and worldwide. Cocaine remains one of the most widely used illegal substances, and despite decades of research, there is no approved medication to treat addiction to cocaine (O'Connor et al., 2014; Skolnick, 2015; Czoty et al., 2016). Ligands acting at receptors of the dopamine D₂ family (D₂/D₃/D₄) modulate cocaine self-administration behavior in laboratory animals: agonists produce leftward shifts of the cocaine dose-effect function, whereas antagonists produce rightward shifts consistent with

surmountable antagonism (Bergman et al., 1990; Caine et al., 1999; Barrett et al., 2004). As medication strategies, D₂-preferring or nonsubtype-selective D₂-family antagonists were not promising, largely because of adverse effects limiting the use of effective doses, and because “anticocaine” effects observed with acute administration eroded when given chronically (see the *Discussion*). The D₃ subtype attracted attention as a potential target for treating psychostimulant addiction, owing to its restricted localization and high concentration in parts of the mesolimbic reward pathway, its high affinity for dopamine, and the differential alteration of D₂ versus D₃ receptor availability as a consequence of psychostimulant use (for review see Heidbreder and Newman, 2010; Keck et al., 2015; Sokoloff and Le Foll, 2017). Specifically, postmortem and positron emission tomography studies suggest that at least some psychostimulant users, especially heavy users, have elevated D₃ receptor availability and decreased D₂ receptor availability relative to controls (Staley and Mash,

This research was supported by the National Institutes of Health National Institute on Drug Abuse [Grants R00DA027825 (to M.T.), T32DA07252 (to A.C.B.), R01DA026946 (to S.S.N.), and R29DA12142 (to S.B.C.)]. M.T. was also supported by funds from Psychiatric Centre Copenhagen while completing portions of the manuscript.

¹Current affiliation: KemPharm, Durham, North Carolina.
<https://doi.org/10.1124/jpet.117.241141>.

ABBREVIATIONS: ANOVA, analysis of variance; FR, fixed ratio; L-741,626, 3-[[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]methyl-1*H*-indole]; NPA, *R*-(–)-norpropylapomorphine; PD-128,907, (4*aR*,10*bR*)-3,4*a*,4,10*b*-tetrahydro-4-propyl-2*H*,5*H*-[1]benzopyrano-[4,3-*b*]-1,4-oxazin-9-ol hydrochloride; PF-592,379, 5-[(2*R*,5*S*)-5-methyl-4-propylmorpholin-2-yl]pyridin-2-amine; PG01037, *N*-[(*E*)-4-[4-(2,3-dichlorophenyl)piperazin-1-yl]but-2-enyl]-4-pyridin-2-ylbenzamide; RGH-237, *N*-[4-[4-(3-aminocarbonyl-phenyl)-piperazin-1-yl]-butyl]-4-bromo-benzamide; SCH 23390, (*R*)-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; SCH 39166, (6*aS*-*trans*)-11-chloro-6,6*a*,7,8,9,13*b*-hexahydro-7-methyl-5*H*-benzo[*d*]naphth[2,1-*b*]azepin-12-ol].

1996; Segal et al., 1997; Boileau et al., 2012; but see Meador-Woodruff et al., 1995). In rats and monkeys, long-term cocaine exposure was shown to increase D_3 receptor availability, decrease D_2 receptor availability, and/or decrease D_2/D_3 ratios (Le Foll et al., 2002; Neisewander et al., 2004; Nader et al., 2006; Collins et al., 2011). Unlike D_2 receptor antagonists, D_3 receptor antagonists administered acutely do not decrease cocaine self-administration under experimental conditions in which cocaine is available at relatively low cost (e.g., low response requirement, no competing reinforcers), but they can decrease cocaine taking under higher cost conditions, although selectivity over reduction in food-reinforced responding was often moderate (Heidbreder and Newman, 2010; Sokoloff and Le Foll, 2017).

Critical review of laboratory animal evaluations of candidate medications strongly supports the notion that predictive validity is dependent on the inclusion of chronic dosing regimens, whereas acute-only results have often been misleading (Haney and Spealman, 2008; Czoty et al., 2016; see specific examples in the *Discussion*). Furthermore, effects on cocaine self-administration (i.e., direct reinforcing effects of cocaine) have predicted clinical efficacy better than modulation of subjective or conditioned effects alone (Comer et al., 2008; Haney and Spealman, 2008). One type of self-administration assay, choice procedures, is gaining popularity, with various proposed advantages over single-reinforcer assays (Banks et al., 2015a; Banks and Negus, 2017). Choice procedures allow behavior allocation to be assessed independently of rates of responding, and they also allow simultaneous evaluation of effects on cocaine and food intake. Most importantly for this investigation, we have found that choice procedures in rats are well suited to comparing acute versus chronic effects of pharmacological manipulations. We previously used a choice procedure to compare acute and subchronic effects of *d*-amphetamine, and of the D_2/D_3 partial agonist aripiprazole, obtaining results in line with human studies (Thomsen et al., 2008, 2013; Greenwald et al., 2010; Haney et al., 2011). Other evidence also supports a concordance between effects of medication maintenance on cocaine choice in preclinical studies, cocaine choice in human laboratory studies, and cocaine use in clinical trials (Foltin et al., 2015; Czoty et al., 2016; Johnson et al., 2016; Lile et al., 2016).

The primary objective of this study was to evaluate dopamine D_3 receptor-selective (or D_3 -preferring) ligands, both agonists and antagonists, as a continuous (sub)chronic treatment, in a direct comparison with D_2 receptor ligands. The effects of chronic administration were also compared with acute dosing effects. Table 1 shows the ligands tested and their respective affinities for D_2 and D_3 receptors, with references from previously published sources. All compounds penetrate the blood-brain barrier, except for RGH-237 [*N*-(4-[4-(3-aminocarbonyl-phenyl)-

piperazin-1-yl]-butyl]-4-bromo-benzamide], which showed poor brain penetration but still showed behavioral effects consistent with partial D_3 receptor agonist activity (Heidbreder and Newman, 2010; Mason et al., 2010; Morgan et al., 2012; and see references in Table 1). We tested the hypothesis that D_2 and D_3 receptor ligands would differ in chronic as well as acute effects and, specifically, that chronic administration of a D_3 receptor ligand could decrease cocaine self-administration in the cocaine versus food choice procedure in rats.

Materials and Methods

Animals

Experimentally naïve male Sprague-Dawley rats were acquired at 8 weeks of age from Charles River Laboratories (Wilmington, MA) and acclimated to the laboratory for at least a week before training began. Rats were housed individually with free access to water in a temperature- and humidity-controlled facility maintained on a 12-hour/12-hour light/dark cycle (lights on at 07:00). Rats were fed approximately 17 g standard rat chow daily (Rat Diet 5001; PMI Feeds, Inc., St. Louis, MO), adjusted to maintain a healthy 400–500 g body weight. For enrichment, “treats” were provided once or twice weekly, typically bacon-flavored biscuits (5 g; Bio-Serve, Frenchtown, NJ). Behavioral testing was conducted during the light phase. Husbandry and testing complied with the guidelines of the National Institutes of Health Committee on Laboratory Animal Resources, and all protocols were approved by the McLean Hospital Institutional Animal Care and Use Committee.

Apparatus

Operant conditioning chambers (21 cm × 29.5 cm × 24.5 cm) and associated hardware from MED Associates (Georgia, VT) were placed within sound-attenuating cubicles equipped with a house light and an exhaust fan. Each chamber contained three response levers 3 cm above the grid floor, two “reinforcer” levers (referred to as the “left” and “right” levers) on one wall, and a third “observer” lever centered on the opposite wall. A steel cup between the reinforcer levers, 2 cm above the floor, served as a receptacle for the delivery and consumption of liquid food reinforcers. A three-light array (red, yellow, and green) was located above the right lever and illuminated to signify the availability of food. An identical array with one additional yellow light was located above the left lever and was used to signal the cocaine dose available. A white light was located above the observer lever. Each cubicle also contained two syringe pumps (3.3 rpm, model PHM-100, MED Associates, Georgia, VT) for the delivery of liquid food and intravenous cocaine, respectively, through Tygon tubing. Cocaine was delivered using a single-channel fluid swivel (MS-1; Lomir Biomedical, Malone, NY) mounted on a balance arm, which allowed rats free movement.

Operant Training and Surgery

Rats were trained and tested in a cocaine versus food choice procedure as previously described (Thomsen et al., 2008, 2013,

TABLE 1

Classifications based on relative efficacies and affinities for dopamine D_2 or D_3 receptors determined in vitro, from published reports.

Ligand	Classification	Binding Selectivity ($D_2 - K_i/D_3 - K_i$)	Reference
NPA	D_2/D_3 agonist	0.6–8	Freedman et al., 1994; Sautel et al., 1995
Terguride	D_2/D_3 partial agonist	1.1	Millan et al., 2002
L-741,626	D_2 -preferring antagonist	0.02–0.07	Kulagowski et al., 1996; Millan et al., 2000; Caine et al., 2002
PD-128,907	D_3 -preferring agonist	6.3–210	Pugsley et al., 1995; Sautel et al., 1995
PF-592,379	D_3 -selective agonist	>470	Attkins et al., 2010; Collins et al., 2012
RGH-237	D_3 -selective partial agonist	>1000	Gyertyán et al., 2007
PG01037	D_3 -selective antagonist	133	Grundt et al., 2005

2014). Between the completion of the acute dosing experiments and the start of the chronic dosing experiments, the procedure was slightly modified in two ways to allow for more efficient training: 1) acute experiments used static levers, whereas retractable levers were used in the chronic experiments; and 2) the reinforcer magnitudes (food concentration and cocaine doses) were adjusted slightly (see below). All other parameters and training methods were identical and are briefly outlined below.

Food Training. First, lever pressing was acquired in daily 2-hour sessions, with liquid food (75 μ l vanilla-flavored Ensure nutrition drink; Abbott Laboratories, Abbott, IL) reinforcing responding under a fixed ratio (FR) 1 schedule of reinforcement. Food was diluted to 56% in water for acute dosing experiments and to 32% for chronic experiments. Illumination of the triple cue light above the right lever signaled food availability, and cues were turned off at reinforcer delivery. Responses on the other levers (cues off) were recorded but had no scheduled consequences. When ≥ 50 reinforcers were earned within one 2-hour session, the response requirement was gradually increased to FR 5. When rats again earned ≥ 50 reinforcers, a chain schedule was introduced in which one response on the observer lever initiated an FR 5 schedule on the right lever (see Thomsen et al., 2013 for details). When rats again earned ≥ 50 food reinforcers per session for five consecutive sessions (training criteria), they were implanted with catheters.

Surgery and Catheter Maintenance. Rats were anesthetized with an isoflurane/oxygen vapor mixture and implanted with chronic indwelling jugular vein catheters (see Thomsen and Caine, 2005). A catheter was inserted 3.7 cm into the external jugular vein and anchored to the vein. The catheter ran subcutaneously to the midscapular region where the base was located. Single doses of an analgesic (5 mg/kg ketoprofen) and an antibiotic (10 mg/kg amikacin) were administered subcutaneously immediately before surgery. Rats were allowed approximately 7 days of recovery before being given access to intravenous cocaine. During this period, a prophylactic dose of cefazolin (30–40 mg/kg) was delivered daily through the catheter. Thereafter, catheters were flushed daily with sterile saline containing heparin (3 USP U/0.1 ml). Catheter patency was verified daily by withdrawing and immediately reinfusing a few microliters of blood through the catheter (enough for visual detection of blood); if blood could not be withdrawn, catheter patency was tested by administering 0.05–0.1 ml of a ketamine-midazolam mixture (15 + 0.75 mg/ml) through the catheter and observing prominent signs of sedation within 3 seconds of infusion. Only data collected with demonstrated patent catheters were included.

Cocaine Self-Administration Training. Cocaine self-administration started with daily 2-hour sessions, under an FR 1 FR 1 timeout 20 seconds chain schedule, left lever active. Responses on the right lever were recorded and reset the ratio requirement on the left lever. Sessions started with a noncontingent “priming” cocaine infusion, and then flashing of the full cue light array over the left lever indicated the availability of cocaine at 1.0 mg/kg per infusion. Cues were turned off at reinforcer delivery. The response requirement was gradually increased to FR 1 FR 5, and training continued until cocaine self-administration behavior stabilized, which was defined as three consecutive sessions with ≥ 10 mg/kg cocaine self-administered per 2-hour session and $\geq 90\%$ of left plus right lever responses emitted on the drug-reinforced lever. Sessions were then modified to include five 20-minute components of cocaine availability (1.0 mg/kg per infusion), with 2-minute intercomponent timeout periods, using the same schedule of reinforcement. This schedule remained in effect until behavior stabilized (i.e., ≥ 10 mg/kg cocaine self-administered per session and ≥ 1 reinforcer earned per component). Rats were then given access to 0.32 mg/kg cocaine per infusion for at least 1 day before choice training began, to observe increased rates of responding.

Cocaine versus Food Choice Training. Daily sessions consisted of five 20-minute components separated by 2-minute timeout periods. Responding was reinforced under a FR 1 [concurrent FR 5 FR 5] chain schedule, with responding on the right lever being reinforced

with liquid food and responding on the left being reinforced with cocaine infusions of increasing doses for each component as follows: 0, 0.032, 0.1, 0.32, and 1.0 mg/kg per infusion (in the acute experiment) or 0, 0.056, 0.18, 0.56, and 1.0 mg/kg per infusion (in the chronic experiment). Responding on one reinforcer lever reset the ratio requirement on the other. Cocaine doses were achieved by varying the infusion time, adjusted to each rat's body weight. The light array over the left lever flashed when cocaine was available, indicating the unit dose available: no light for 0, green for 0.032/0.056 mg/kg per infusion, green plus yellow for 0.10/0.18 mg/kg per infusion, green plus yellow plus red for 0.32/0.56 mg/kg per infusion, and green plus yellow plus red plus yellow for 1.0 mg/kg per infusion; cues were turned off at reinforcer delivery. Per component, 15 total reinforcers were available (completion of the response requirement on the left lever during availability of the zero cocaine dose counted as one reinforcer). If all 15 reinforcers were earned in less than 20 minutes, all stimulus lights were extinguished, and responding had no scheduled consequences for the remainder of the 20-minute component. Choice training continued until behavior stabilized satisfying the criteria: 1) three consecutive sessions with ≥ 5 reinforcers/component earned in components 1–4 and 2) ≥ 1 reinforcer earned in component 5, and 3) with the dose of cocaine producing $\geq 80\%$ cocaine choice on any given day remaining within one-half log unit of the 3-day mean.

Testing

Once training was completed, we tested the effects of D₂- and D₃-preferring agonists, partial agonists, and antagonists, under acute and chronic dosing conditions. Rats were allocated to test groups randomly. As much as possible, doses of each drug were tested within subjects, but due to attrition, additional rats had to be added to some dose groups. Rats had at least three sessions of baseline between acute doses or at least 1 week between chronic doses. Baseline choice behavior had to satisfy the original criteria (see above) in order for a rat to test again. If the cocaine dose maintaining $\geq 80\%$ cocaine choice was within one-half log unit of the previously established baseline, a rat could test again; if not, a new stable 3-day baseline was established with the criteria described above.

In the acute treatment experiment, we tested the D₂ agonist *R*-(–)-norpropylapomorphine (NPA; 0.01, 0.032, 0.1, 0.32, 0.56, and 1.0 mg/kg), the D₂/D₃ partial agonist terguride (0.032, 0.1, 0.32, 0.56, and 1.0 mg/kg), the D₂ antagonist L-741,626 [3-[[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]methyl-1*H*-indole] (0.32, 1.0, 3.2, 5.6 mg/kg), the D₃ agonist PD-128,907 [(4*aR*,10*bR*)-3,4*a*,4,10*b*-tetrahydro-4-propyl-2*H*,5*H*-[1]benzopyrano-[4,3-*b*]-1,4-oxazin-9-ol hydrochloride] (0.1, 0.32, 1.0, 3.2, and 5.6 mg/kg), the D₃ partial agonist RGH-237 (10, 32, 56 mg/kg), and the D₃ antagonist PG01037 [N-[(*E*)-4-[4-(2,3-dichlorophenyl)piperazin-1-yl]but-2-enyl]-4-pyridin-2-ylbenzamide] (1.0, 3.2, 10, 18, and 32 mg/kg), as well as corresponding vehicles, with doses presented in counterbalanced sequence. All drugs were administered intraperitoneally, 10 minutes before the session.

In the chronic treatment experiment, the D₃-preferring agonist PD-128,907 was replaced by the then newly available, more selective D₃ agonist PF-592,379 [(5-[(2*R*,5*S*)-5-methyl-4-propylmorpholin-2-yl]pyridin-2-amine] (Attkins et al., 2010). We previously reported the effects of acute and chronic administration of the partial D₂/D₃ agonist aripiprazole using the same assay (Thomsen et al., 2008); therefore, partial agonists were not evaluated as chronic treatment in this investigation. Chronic treatment was achieved with the use of osmotic minipumps (Alzet model 2ML1; Durect, Cupertino, CA) that were implanted subcutaneously under brief isoflurane/oxygen vapor anesthesia and delivered drug continuously at a rate of 10 μ l/h. Before implantation, filled minipumps were primed overnight in sterile 0.9% saline at 37–38°C as directed by the manufacturer. On day 1, rats were tested 2 hours after pump implantation, and the pumps were then left in place for 7 days, during which time rats were tested daily as they had been during training. Chronic treatments tested were as follows: NPA (0.00032, 0.001, 0.0032, and 0.01 mg/kg per hour), L-741,626

(0.056, 0.18, 0.32, and 0.56 mg/kg per hour), PF-592,379 (0.56, 1.8, and 3.2 mg/kg per hour), and PG01037 (0.56, 1.8, 3.2, and 5.6 mg/kg per hour). Drug concentrations were adjusted for each rat according to body weight. Treatment was stopped by removing the minipump. We previously verified that 7 days of continuous water administration and presence of the minipumps did not produce any significant changes in choice behavior (Thomsen et al., 2013), and the present data set includes low doses that showed no effect (e.g., NPA, PF-592,379). Therefore, to reduce the number of animal lives needed, we did not include further chronic vehicle groups. Data are reported for the first and last day for brevity, and intervening days typically showed gradual shifts from the acute effects to the chronic effects.

Drugs

Cocaine hydrochloride was provided by the National Institutes of Health National Institute on Drug Abuse (Bethesda, MD). PF-592,379 was supplied by P. Butler and was synthesized at Pfizer (Sandwich, UK) as previously described (Attkins et al., 2010). PG01037 dihydrochloride was supplied by A.H. Newman and was synthesized at the National Institutes of Health National Institute on Drug Abuse Medicinal Chemistry Section as previously described (Grundt et al., 2005). RGH-237 was supplied by I. Gyertyán and synthesized at Gedeon Richter (Budapest, Hungary) as previously described (Gyertyán et al., 2007). All other drugs were purchased from Sigma-Aldrich (St Louis, MO). Cocaine and terguride were dissolved in 0.9% saline. PF-592,379, PD-128,907 hydrochloride, and PG01037 dihydrochloride were dissolved in sterile water. NPA hydrochloride was dissolved in 0.1% ascorbic acid in water, L-741,626 was dissolved in 22% β -cyclodextrin in water, and RGH-237 was dissolved in ethanol and diluted to a final vehicle of 5% ethanol, 47.5% polyethylene glycol, and 47.5% water. Doses reflect the weights of the respective salts.

Data Analysis

The primary dependent variables recorded for each component were 1) number of cocaine injections earned, 2) number of food reinforcers earned, and 3) percent cocaine choice, which was calculated as follows: (number of ratios completed on the cocaine-associated lever $\div$ total number of ratios completed) $\times$ 100. Total cocaine intake per session (in milligrams per kilogram) and total food reinforcers earned per session were also calculated for each rat. Total response rate (total number of responses $\div$ total time responses had scheduled consequences) and response rate on the reinforcer levers alone (calculated using the time these levers were extended) were also recorded but are not reported because they added no significant information on treatment effects, relative to numbers of reinforcers earned. The significance level was set at $P < 0.05$. No data points collected with patent catheters were excluded (no "outliers").

For the acute treatments, two-way analysis of variance (ANOVA) was used to analyze the effects of test drugs and cocaine dose on numbers of cocaine and food reinforcers earned per component, with factors being cocaine dose (repeated measures, within subjects) and treatment dose (between subjects). For the chronic experiment, repeated-measures two-way ANOVA was used to analyze the effects of test drugs and cocaine dose on numbers of cocaine and food reinforcers earned per component, with factors being cocaine dose and treatment day (i.e., baseline, first day, after 1 week). Because all doses of a test compound could not always be tested in each rat (within subjects), each chronic drug dose was analyzed separately, so that test versus baseline could be analyzed within subjects. Significant effects on a test day were scrutinized post hoc by Bonferroni post-test versus vehicle/baseline. In both acute and chronic experiments, the effect of cocaine dose was always highly significant and is not reported for each analysis, for brevity.

The percent cocaine choice data were used to calculate A_{50} values (potency), defined as the dose of cocaine that produced 50% cocaine choice in each rat, and determined by interpolation from two adjacent points spanning 50% cocaine choice. In cases in which cocaine choice

was 50%–60% at the lowest dose, extrapolation was used ($<4\%$ of all values). In cases in which cocaine choice was $>60\%$ at the lowest dose, a value of 0.018 or 0.032 mg/kg per injection was assigned (i.e., quarter-log below the lowest cocaine dose tested, in the acute and chronic experiments, respectively) as a conservative estimate. Because many treatments, especially chronic, produced leftward shifts in the cocaine choice curve, these estimates amounted to 16% of all A_{50} values. Similarly, in cases in which cocaine choice was $<40\%$ at the highest dose, a value of 1.8 mg/kg per injection was assigned (two values, $<0.5\%$ of total). Group means and 95% confidence intervals were calculated from the log(10) of individual A_{50} values but are reported transformed back to linear values for ease of reading. In some cases, responding was completely suppressed in one or more rats for some time/dose points, resulting in missing values for the choice measure, precluding the use of repeated-measures ANOVA for this measure. Instead, the log-transformed A_{50} values were compared by one-way ANOVA for the acute experiment (factor: dose, between subjects) and two-way ANOVA for the chronic experiment (factors: treatment dose, between subjects; test day, within subjects, using pooled baseline data for all rats tested with any dose of that drug). Significant effects or interactions were examined by one-way ANOVA for each time point. Significant effects were followed by the Dunnett multiple-comparisons test versus vehicle or baseline. Total cocaine intake and total food reinforcers earned per session were analyzed in the same way as A_{50} values.

Results

Acute Administration

In a first experiment, we tested the acute effects of pre-treatment with D_2 and D_3 agonists, partial agonists, and antagonists on cocaine versus food choice. Figure 1 shows the effects of the D_2 agonist NPA, the D_2/D_3 partial agonist terguride, and the D_2 antagonist L-741,626 on numbers of cocaine injections and food reinforcers earned, as well as percent cocaine choice. To avoid crowding, three doses were selected for graphical presentation for each ligand, omitting some low and/or intermediate doses. Likewise, Fig. 2 shows the effects the D_3 agonist PD-128,907, the D_3 partial agonist RGH-237, and the D_3 antagonist PG01037. The corresponding potencies of cocaine to produce 50% cocaine choice (A_{50} values) are reported in Table 2 (all doses tested). Total cocaine intake per session and total food reinforcers were also calculated and are presented in Fig. 3 for all doses tested.

The D_2 agonist NPA produced dose-dependent leftward shifts in the cocaine reinforcers dose-effect curve, with a significant cocaine dose by NPA dose interaction [$F(24,140) = 2.29$, $P < 0.01$]; effects of 0.32, 0.56, and 1.0 mg/kg reached significance post hoc ($P < 0.01$; Fig. 1). NPA also produced marked decreases in numbers of food reinforcers earned (NPA dose [$F(6,140) = 9.47$, $P < 0.0001$], interaction [$F(24,140) = 3.71$, $P < 0.0001$]), with doses from 0.032 mg/kg and up producing significant decreases ($P < 0.01$). This reallocation of behavior from food toward cocaine resulted in dose-dependent leftward shifts in the cocaine choice curve, with corresponding decreases in A_{50} values [$F(6,32) = 3.92$, $P < 0.01$ (see Table 2 for statistical analysis)]. NPA's effects on reinforcers earned resulted in dose-dependent decreases in both total cocaine intake [$F(6,35) = 2.94$, $P < 0.05$] and total food reinforcers earned [$F(6,35) = 9.49$, $P < 0.0001$], although post hoc comparisons on cocaine intake did not reach significance (Fig. 3).

The D_2/D_3 partial agonist terguride did not affect cocaine reinforcers earned significantly, up to doses that significantly suppressed food reinforcers (terguride dose [$F(5,128) = 9.30$,

Fig. 1. Acute dosing effects of dopamine D₂-preferring ligands on concurrent cocaine self-administration and food-reinforced responding as a function of cocaine dose. The abscissae show the unit dose of cocaine (in milligrams per kilogram per injection), and the ordinates show cocaine injections earned (top), food reinforcers earned (center), and percent cocaine choice (bottom), per component. Group sizes are presented in Table 2. Choice data for higher pretreatment doses may have a lower group size because of missing values and are not shown when responding was reduced to the point that percent choice could be calculated for fewer than two rats. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$ (versus vehicle, Bonferroni post-test after significant ANOVA).

$P < 0.0001$], interaction [$F(20,128) = 5.74, P < 0.0001$], significant at 0.1, 0.56, and 1.0 mg/kg ($P < 0.05$). Terguride did not affect cocaine choice curves or A₅₀ values consistently or significantly (Table 2). Terguride also failed to affect total cocaine intake significantly but did produce significant decreases in total food reinforcers earned [$F(5,31) = 10.7, P < 0.0001$] (see Fig. 3).

The D₂ antagonist L-741,626 produced effects opposite to NPA on the cocaine reinforcers curve (i.e., dose-dependent rightward shifts) (L-741,626 dose [$F(4,136) = 4.74, P < 0.01$], interaction [$F(16,136) = 5.98, P < 0.0001$]). Effects of 3.2 and 5.6 mg/kg reached significance ($P < 0.001$; Fig. 1). L-741,626 also decreased the numbers of food reinforcers earned (L-741,626

Fig. 2. Acute dosing effects of dopamine D_3 -preferring ligands on concurrent cocaine self-administration (top), food-reinforced responding (center), and percent cocaine choice (bottom), as a function of cocaine dose. Group sizes are presented in Table 2. Other details are as in Fig. 1.

dose [$F(4,136) = 12.0$, $P < 0.0001$], interaction [$F(16,136) = 5.64$, $P < 0.0001$], at the same doses that affected cocaine reinforcers, 3.2 and 5.6 mg/kg ($P < 0.05$). The combined effect on the cocaine choice curve was dose-dependent rightward shifts with corresponding increases in A_{50} values [$F(3,27) = 2.91$, $P = 0.05$], significant at the highest dose ($P < 0.05$; Table 2). Although intermediate doses of L-741,626 increased the number of high-dose cocaine injections earned, total cocaine intake was only increased marginally; however, the highest dose of L-741,626 decreased cocaine intake [$F(4,40) = 5.12$, $P < 0.01$]. The same profile was apparent for total food reinforcers earned [$F(4,40) = 18.0$, $P < 0.0001$] (see Fig. 3).

The D_3 agonist PD-128,907 produced downward shifts in the cocaine reinforcer curve at intermediate doses and a downward/leftward shift at the highest dose (treatment by cocaine interaction [$F(20,160) = 2.32$, $P < 0.001$]). Effects were significant at 0.32, 3.2, and 5.6 mg/kg ($P < 0.05$; Fig. 2). PD-128,907 also produced marked downward and

downward/rightward shifts in the food reinforcers curve (PD-128,907 dose [$F(5,160) = 6.69$, $P = 0.0001$], interaction [$F(20,160) = 4.79$, $P < 0.0001$]), with significant effects at doses from 0.1 mg/kg and up ($P < 0.05$). The effect on percent cocaine choice was mixed, with small, nonsignificant rightward shifts at intermediate doses and significant leftward shifts at the higher doses. Thus, PD-128,907 modulated A_{50} values [$F(5,35) = 3.62$, $P < 0.01$], with a significant decrease at 5.6 mg/kg (see Table 2). Effects of PD-128,907 on total cocaine intake were modest and not statistically significant (Fig. 3), whereas effects on food were more pronounced [$F(5,41) = 7.02$, $P < 0.001$].

The D_3 partial agonist RGH-237 and the D_3 antagonist PG01037 each produced moderate, nonsignificant leftward shifts in the cocaine reinforcer curve at lower doses and moderate downward shifts at high doses (Fig. 2). However, the effect reached significance only for RGH-237 (interaction [$F(12,112) = 1.90$, $P < 0.05$]), the highest dose of 56 mg/kg

TABLE 2
Changes in cocaine choice A₅₀: acute administration experiment

Values are given as group sizes (n) and group means (95% confidence limits). Doses are given in milligrams per kilogram per injection of cocaine that produced 50% cocaine choices.

D ₂										D ₃																			
Agonist (NPA)					Antagonist (Terguride)					Antagonist (L-741,626)					Agonist (PD-128,907)					Partial Agonist (RGH-237)					Antagonist (PG01037)				
Dose	n	Group Mean	Dose	n	Group Mean	Dose	n	Group Mean	Dose	n	Group Mean	Dose	n	Group Mean	Dose	n	Group Mean	Dose	n	Group Mean	Dose	n	Group Mean						
Vehicle	7	0.18 (0.11–0.29)	Vehicle	7	0.15 (0.11–0.21)	Vehicle	8	0.21 (0.16–0.28)	Vehicle	11	0.15 (0.11–0.19)	Vehicle	8	0.21 (0.15–0.27)	Vehicle	6	0.15 (0.11–0.21)	Vehicle	6	0.15 (0.11–0.21)	Vehicle	6	0.15 (0.11–0.21)						
0.01	5	0.16 (0.09–0.27)	0.032	4	0.12 (0.06–0.26)	0.32	8	0.21 (0.15–0.27)	0.10	6	0.19 (0.17–0.20)	0.10	8	0.11 (0.07–0.20)	1.0	5	0.22 (0.15–0.34)	1.0	5	0.22 (0.15–0.34)	1.0	5	0.22 (0.15–0.34)						
0.032	6	0.06 (0.02–0.18)	0.10	7	0.15 (0.10–0.22)	1.0	8	0.29 (0.17–0.48)	0.32	7	0.29 (0.15–0.57)	0.32	8	0.15 (0.07–0.30)	3.2	8	0.14 (0.06–0.33)	3.2	8	0.14 (0.06–0.33)	3.2	8	0.14 (0.06–0.33)						
0.10	6	0.03 (0.02–0.08)*	0.32	7	0.14 (0.10–0.20)	3.2	9	0.44 (0.27–0.71)*	1.0	8	0.21 (0.15–0.29)	1.0	8	0.24 (0.17–0.33)	10	8	0.14 (0.09–0.20)	10	8	0.14 (0.09–0.20)	10	8	0.14 (0.09–0.20)						
0.32	7	0.03 (0.01–0.06)**	0.56	6	Not calculated	5.6	6	Not calculated	3.2	8	0.15 (0.05–0.44)*	3.2	8	0.15 (0.05–0.44)*	18	6	Not calculated	18	6	Not calculated	18	6	Not calculated						
0.56	6	0.03 (0.01–0.06)**	1.0	6	Not calculated				5.6	6	0.05 (0.01–0.14)*	5.6	6	0.05 (0.01–0.14)*	32	8	Not calculated	32	8	Not calculated	32	8	Not calculated						
1.0	4	0.04 (0.01–0.17)																											

Not calculated indicates that responding was suppressed completely in more than one-half of the animals, resulting in missing percent choice values.
 * $P < 0.05$; ** $P < 0.01$ versus vehicle (Dunnett multiple-comparisons test after significant ANOVA).

producing a significant downward shift ($P < 0.05$). Both ligands dose-dependently decreased the number of food reinforcers earned (RGH-237 by cocaine interaction [$F(12,112) = 1.92, P < 0.05$]; PG01037 dose [$F(5,136) = 17.0, P = 0.0001$], interaction [$F(20,136) = 5.43, P < 0.0001$]). RGH-237 produced significant decreases at 10 and 56 mg/kg ($P < 0.05$), PG01037, at 18 and 32 mg/kg ($P < 0.0001$). Neither ligand affected cocaine choice curves or A₅₀ values systematically or significantly (Table 2). Likewise, neither drug affected total cocaine intake significantly, but PG01037 did decrease total food reinforcers earned dose-dependently [$F(5,35) = 17.9, P < 0.0001$], as shown in Fig. 3.

Chronic Administration

Figure 4 shows the acute and chronic effects of continuous administration of the D₂ agonist NPA and the D₂ antagonist L-741,626 on numbers of cocaine injections and food reinforcers earned and percent cocaine choice, as a function of treatment dose (one dose per panel "column"). Figure 5 shows the acute and chronic effects of continuous administration of the D₃ agonist PF-592,379 and the D₃ antagonist PG01037 in the same fashion. Data are reported for the first and last day for brevity, and intervening days typically showed gradual shifts from the acute effects to the chronic effects.

The corresponding potencies of cocaine to produce 50% cocaine choice (A₅₀ values) are reported in Table 3. Total-session cocaine intake and total food reinforcers were also calculated, and are presented in Fig. 6.

The D₂ agonist NPA produced leftward and downward shifts in the cocaine self-administration curve, with marked tolerance after a week of treatment. Cocaine reinforcers were affected significantly at the two highest doses, as a function of treatment day: at 0.0032 mg/kg per hour (cocaine dose by treatment interaction [$F(8,50) = 4.05, P < 0.001$]) and at 0.01 mg/kg per hour (treatment [$F(2,50) = 13.4, P < 0.0001$], interaction [$F(8,50) = 3.87, P < 0.01$]). In the same dose range, NPA significantly decreased the number of food reinforcers earned, but this effect was not generally diminished after chronic administration: at 0.0032 mg/kg per hour (treatment [$F(2,50) = 8.10, P < 0.001$], interaction [$F(8,50) = 3.87, P < 0.01$]), and at 0.01 mg/kg per hour (main [$F(2,50) = 4.32, P < 0.05$], interaction [$F(8,50) = 2.92, P < 0.001$]). Percent cocaine choice was shifted to the left, with corresponding decreases in A₅₀ values (treatment day [$F(1,30) = 5.20, P < 0.05$]), although the effect did not reach statistical significance on specific days (Table 3). The shift in the cocaine dose-effect curve toward the lower cocaine doses resulted in a significant decrease in total cocaine intake on day 1, but this effect was abolished after a week of treatment (see Fig. 6; effect of treatment dose, treatment time, and interaction all $P \leq 0.001$). Total food intake was decreased as a function of NPA dose [$F(4,60) = 3.04, P < 0.05$], with no effect of treatment time or dose by time interaction (i.e., no significant tolerance).

Conversely, the D₂ antagonist L-741,626 produced rightward shifts in the cocaine curve, which showed a high degree of tolerance up until the highest dose (0.56 mg/kg per hour), which produced a downward shift only as chronic treatment, suggesting drug accumulation or perhaps sensitization (see Fig. 4 for statistical details). L-741,626 also decreased the number of food reinforcers earned, and this effect showed tolerance only at the two lowest doses. In fact, exacerbation of the effect upon chronic administration was apparent at the

Fig. 3. Acute effects of dopamine D₂-preferring or D₃-preferring ligands on total cocaine intake and total food reinforcers per session. The abscissae show the dose of pretreatment drug (in milligrams per kilogram), and the ordinates show total cocaine intake (in milligrams per kilogram per session) (top) or total food reinforcers earned per session (bottom). Group sizes are presented in Table 2. * $P < 0.05$; ** $P < 0.01$ (Dunnett multiple-comparisons test versus vehicle after significant ANOVA).

higher doses. L-741,626 also affected cocaine choice, as measured by A_{50} values, differentially as acute and chronic treatment (two-way ANOVA, effect of L-741,626 dose [$F(3,28) = 4.42, P < 0.05$], treatment day [$F(1,28) = 12.1, P < 0.01$], and dose by time interaction [$F(3,28) = 3.46, P < 0.05$]). Specifically,

choice curves were shifted to the right, and A_{50} values increased, on day 1 [$F(4,31) = 4.09, P < 0.01$], with the converse effect after 1 week of treatment [$F(3,28) = 3.12, P < 0.05$] (see Table 3). As shown in Fig. 6, the rightward shift in the cocaine curve (i.e., shift toward higher cocaine doses) resulted in an

Fig. 4. Acute versus chronic effects of continuously administered dopamine D₂-preferring ligands on concurrent cocaine self-administration and food-reinforced responding. Data from baseline, day 1 (2 hours of administration), and day 7 (1 week of continuous administration) are shown. The abscissae show the unit dose of cocaine (in milligrams per kilogram per injection), and the ordinates show cocaine injections earned (top), food reinforcers earned (center), and percent cocaine choice (bottom), per component. Group sizes are presented in Table 3. Choice data for higher pretreatment doses may be a lower group size because of missing values and are not shown when responding was reduced to the point that percent choice could be calculated for fewer than two rats. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$ (versus baseline, Bonferroni post-test after significant ANOVA). Red asterisks refer to day 1, and blue asterisks refer to the chronic 1-week test.

Fig. 5. Acute versus chronic effects of continuously administered dopamine D_3 -preferring ligands on concurrent cocaine self-administration, food-reinforced responding, and percent cocaine choice. Group sizes are presented in Table 3. Other details are as in Fig. 4.

increase in total cocaine intake acutely, and this effect dissipated after chronic administration (L-741,626 dose by time interaction [$F(4,31) = 3.55$, $P < 0.05$]). Total food intake was decreased both acutely and chronically (see Fig. 6; effect of

treatment dose [$F(4,31) = 8.41$, $P = 0.0001$], dose by time interaction [$F(4,31) = 3.68$, $P < 0.05$]).

The D_3 agonist PF-592,379 had no effect on numbers of cocaine injections earned acutely, up to doses that decreased

TABLE 3

Changes in cocaine choice A₅₀: chronic administration experimentValues are given as group sizes (*n*) and group means (95% confidence limits). Doses are given in milligrams per kilogram per injection cocaine.

Ligand	<i>n</i>	Day 1	1 Week
NPA			
Baseline	11	0.06 (0.04–0.07)	–
0.00032	6	0.05 (0.03–0.08)	0.05 (0.03–0.08)
0.001	6	0.08 (0.04–0.17)	0.05 (0.03–0.08)
0.0032	6	0.04 (0.03–0.06)	0.04 (0.03–0.06)
0.01	6	0.05 (0.03–0.08)	0.03 (0.03–0.04)
L-741,626			
Baseline	15	0.09 (0.07–0.10)	–
0.056	6	0.19 (0.11–0.32)*	0.08 (0.06–0.12)
0.18	6	0.14 (0.08–0.24)	0.10 (0.10–0.10)
0.32	5	0.08 (0.04–0.13)	0.05 (0.03–0.09)**
0.56	4	0.11 (0.10–0.13)	Not calculated
PF-592,379			
Baseline	8	0.07 (0.06–0.09)	–
0.56	6	0.10 (0.06–0.16)	0.07 (0.05–0.11)
1.8	6	0.07 (0.04–0.10)	0.05 (0.03–0.08)
3.2	5	0.06 (0.04–0.11)	0.03 (0.03–0.03)*
PG01037			
Baseline	21	0.08 (0.06–0.10)	–
0.56	6	0.12 (0.08–0.19)	0.11 (0.05–0.24)
1.8	6	0.08 (0.06–0.12)	0.13 (0.04–0.39)
3.2	6	0.20 (0.11–0.38)*	0.15 (0.07–0.33)
5.6	4	0.07 (0.03–0.14)	Not calculated

Not calculated indicates that responding was suppressed completely in more than one-half of the animals, resulting in missing percent choice values.

P* < 0.01; *P* < 0.05; versus baseline (Dunnett multiple-comparisons test after significant ANOVA).

food reinforcers. However, the highest dose (3.2 mg/kg per hour) produced a leftward or upward shift in the ascending limb of the cocaine dose-effect curve after a week of continuous administration (see Fig. 5; treatment [$F(2,40) = 5.89$, $P < 0.01$], interaction [$F(8,40) = 5.91$, $P < 0.0001$]). This shift was

not accompanied by a decrease in the high-dose cocaine injections (descending limb). A trend toward the same effect was apparent at the intermediate dose of 1.8 mg/kg per hour. Food reinforcers similarly were only affected significantly at the highest dose, which produced a decrease both acutely and chronically (treatment [$F(2,40) = 8.79$, $P < 0.001$], interaction [$F(8,40) = 3.79$, $P < 0.01$]). Thus, after chronic treatment with the D₃ agonist, behavior was reallocated from food toward cocaine taking, and percent cocaine choice was shifted leftward, with decreased A₅₀ values (two-way ANOVA effect of treatment day [$F(1,21) = 5.78$, $P < 0.05$] and dose [$F(3,21) = 1.22$, $P < 0.05$]), significant after chronic administration only [$F(13,21) = 5.94$, $P < 0.01$], Table 3). Despite this shift, seen only at the lowest unit dose of cocaine, total cocaine intake was not significantly modified by PF-592,379, acutely or chronically (Fig. 6). Food intake was suppressed moderately, and as much or more so by chronic administration relative to acute administration (effect of PF-592,379 dose [$F(3,21) = 4.43$, $P < 0.05$]).

The D₃ antagonist PG01037 had no effect on numbers of cocaine injections earned at most doses, acutely or chronically but did produce a downward shift in the cocaine curve at the intermediate-high dose of 3.2 mg/kg per hour, with partial tolerance after 1 week of treatment (treatment day [$F(2,50) = 4.86$, $P < 0.05$], interaction [$F(8,50) = 2.45$, $P < 0.05$]). This decrease in cocaine choice was accompanied by a moderate and nonsignificant increase in food reinforcers. However, the highest dose (5.6 mg/kg per hour PG01037) decreased food-reinforced behavior significantly without affecting cocaine, and this effect on food remained as pronounced or more pronounced after 1 week (see Fig. 5; treatment [$F(2,30) = 17.4$, $P = 0.0001$], interaction [$F(8,30) = 5.99$, $P < 0.0001$]). Consequently, percent cocaine choice was shifted moderately

Fig. 6. Acute versus chronic effects of continuously administered dopamine D₂-preferring or D₃-preferring ligands on total cocaine intake and total food reinforcers per session. Data from baseline, day 1 (2 hours of administration), and day 7 (1 week of continuous administration) are shown. The abscissae show the dose of pretreatment drug (in milligrams per kilogram), and the ordinates show total cocaine intake (in milligrams per kilogram per session) (top) or total food reinforcers earned per session (bottom). Group sizes are presented in Table 3. **P* < 0.05; ***P* < 0.01 (Dunnett multiple-comparisons test versus baseline after significant ANOVA).

to the right with the treatment dose of 3.2 mg/kg per hour, as supported by a significant increase in A_{50} values (effect of dose PG01037 [$F(4,37) = 2.85, P < 0.05$]; see Table 3). The doses of 0.56 and 1.8 mg/kg per hour doses produced only modest, nonsignificant rightward shifts in the cocaine choice curve, indicating a narrow dose window or variable effect of PG01037. Although 3.2 mg/kg per hour appeared to be the most effective dose across rats, some individual variability was observed, some rats indicated a decrease in cocaine self-administration at lower doses. The shift produced by 3.2 mg/kg per hour was greatly attenuated after chronic treatment and was only statistically significant on day 1 [$F(4,37) = 4.58, P < 0.01$] (see Table 3). Regardless of treatment time, PG01037 treatment failed to significantly alter total cocaine intake per session, whereas food intake was decreased at the highest dose of PG01037 (effect of dose [$F(4,38) = 3.62, P < 0.05$] (Fig. 6).

Discussion

The dopamine D_3 receptor continues to be of interest as a potential target for cocaine addiction medications. D_3 receptor antagonists have generally failed to decrease the direct reinforcing effects of cocaine but can decrease conditioned responding (for review, see Sokoloff and Le Foll, 2017). However, the evaluation of D_3 receptor ligands has mostly concentrated on acute dosing. Preclinical and clinical studies have demonstrated that chronic administration of dopamine receptor ligands, and dopamine transporter ligands, can affect cocaine intake and other addiction-related effects of cocaine very differently from their acute effects. Nonselective dopamine receptor antagonists (e.g., flupenthixol), D_2 receptor antagonists (e.g., risperidone), and D_1/D_5 receptor antagonists (SCH 39166 [(6*aS-trans*)-11-chloro-6,6*a*,7,8,9,13*b*-hexahydro-7-methyl-5*H*-benzo[*d*]naphth[2,1-*b*]azepin-12-ol] or SCH 23390 [(*R*)-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine]) have been evaluated preclinically and clinically. All showed antagonism of cocaine's effects, including reduced self-administration, as acute dosing but were ineffective or increased cocaine intake and/or subjective effects of cocaine as chronic treatment, with good agreement between human studies (Romach et al., 1999; Grabowski et al., 2000; Haney et al., 2001; Nann-Vernotica et al., 2001; Loebl et al., 2008; Kishi et al., 2013) and laboratory animal studies (Kleven and Woolverton, 1990; Negus et al., 1996; Negus, 2003; Hutsell et al., 2016). Similar effects were obtained with the D_2/D_3 partial agonist aripiprazole (Stoops et al., 2007; Bergman, 2008; Thomsen et al., 2008; Haney et al., 2011; Lofwall et al., 2014).

Conversely to dopamine receptor antagonists, agonist medication strategies using chronic administration of monoamine releasers such as *d*-amphetamine, methamphetamine, phenmetrazine, or their prodrugs decreased cocaine taking and cocaine choice in humans (Grabowski et al., 2001; Shearer et al., 2003; Mooney et al., 2009; Greenwald et al., 2010; Pérez-Mañá et al., 2011; Nuijten et al., 2016), monkeys (Negus, 2003; Negus and Mello, 2003; Czoty et al., 2010, 2011; Banks et al., 2011, 2013, 2015b; Hutsell et al., 2016), and rats (Chiodo et al., 2008; Thomsen et al., 2013). Acutely, amphetamines mimic and increase behavioral and subjective effects of cocaine and increase cocaine intake/choice (Barrett et al., 2004; Thomsen et al., 2013). Thus, both agonist and antagonist dopaminergic

manipulations show either profound tolerance or indeed a complete reversal of effect direction between acute and chronic administration. Therefore, it is becoming clear that potential cocaine addiction medication strategies must be evaluated using chronic or subchronic dosing conditions to better predict effects of clinical use, in which medications will most likely be administered as chronic treatment to promote abstinence.

Although there is mounting evidence to support the efficacy of agonist medications with psychostimulant properties such as *d*-amphetamine (but not of direct dopamine receptor agonists), the acceptance and U.S. Food and Drug Administration approval of those agonist medications is faced with serious challenges based on concerns about their addictive potential and safety (Pérez-Mañá et al., 2011; Minozzi et al., 2015; Negus and Henningfield, 2015). Here, we used a cocaine versus food choice assay in rats to compare acute and chronic dosing effects of dopamine D_2 and D_3 receptor agonists and antagonists. A primary objective of these studies was to evaluate D_3 receptor agonists and antagonists as (sub)chronic treatments and to test the hypothesis that chronic administration may decrease cocaine choice and/or intake, despite the general lack of an acute effect of D_3 receptor-selective ligands on cocaine self-administration. D_2 receptor agonists and antagonists were also tested using acute and chronic treatment regimens to allow for direct comparisons.

Table 4 presents a summary of treatment effects in this investigation, as well as previous results obtained with aripiprazole and *d*-amphetamine for comparison. Acute dosing with D_2 receptor ligands produced results in agreement with previous single-reinforcer experiments (Caine et al., 2000; Haile and Kosten, 2001; Barrett et al., 2004; Rowlett et al., 2007): the agonist NPA shifted the cocaine self-administration dose-effect curve to the left, the antagonist L-741,626 shifted the curve to the right, and the partial agonist had little effect. All three compounds also suppressed food-reinforced responding, which is also consistent with single-reinforcer studies (Barrett et al., 2004). Acute effects of the D_3 receptor ligands differed from this typical agonist/antagonist profile. A flattening of the cocaine self-administration curve was observed with the highest dose of the agonist PD-128,907 and with lower doses of both the partial agonist RGH-237 and of the antagonist PG01037. The variable and nonsignificant increase in self-administration of a low dose of cocaine most likely reflects modulation of the conditioned reinforcing effects of the cocaine-associated cues, rather than an increase in the reinforcing effect of cocaine or direct reinforcing effects of the D_3 receptor ligand, based on previous studies failing to demonstrate reinforcing effects of D_3 receptor-selective ligands, as well as the fact that cocaine choices were not increased in the no-cocaine component in our investigation (Beardsley et al., 2001; Collins and Woods, 2009; Collins et al., 2012). Lower doses of PD-128,907 and higher doses of RGH-237 or PG01037 produced downward shifts of similar magnitude in cocaine and food choices, suggesting nonselective suppression of behavior rather than modulation of cocaine's reinforcing effects specifically. This is consistent with a general lack of effect of D_3 receptor ligands in single-reinforcer cocaine self-administration studies in monkeys and rodents at doses that did not also cause general suppression of behavior (Beardsley et al., 2001; Gál and Gyertyán, 2003; Achat-Mendes et al., 2009; Caine et al., 2012). It is also possible that both stimulation and blockade of D_3 receptors

TABLE 4

Summary of present and previous findings

Effects refer to total cocaine intake per session, total food reinforcers per session, and percent cocaine choice, respectively.

Classification	Ligand	Acute Effects			Chronic Effects		
		Cocaine Intake	Food Intake	Cocaine Choice	Cocaine Intake	Food Intake	Cocaine Choice
D ₂ agonist	NPA	↓	↓	↑	—	↓	(↑)
D ₂ /D ₃ partial agonist	Terguride	—	↓	—	—	↓	↑
D ₂ antagonist	L741,626	↑	↓	↓	—	↓	↑
D ₃ agonist	PD-128,907	—	↓	↑	—	↓	↑
D ₃ agonist	PF-592,379	—	(↓)	—	—	↓	↑
D ₃ partial agonist	RGH-237	—	↓	— or ↓	—	↓	—
D ₃ antagonist	PG01037	(↓)	(↓)	↓	(↑)	↓	(↑)
D ₂ /D ₃ partial agonist	Aripiprazole medium dose ^a	(↑)	(↓)	—	(↓)	↑	↓
D ₂ /D ₃ partial agonist	Aripiprazole high dose ^a	(↑)	(↓)	—	(↓)	↑	↓
Monoamine reuptake inhibitor	<i>d</i> -Amphetamine ^b	↓	↓	↑	(↓)	↑	↓

↓, decrease; ↑, increase; —, no change. Arrows in parentheses indicate trends that did not reach statistical significance.

^aThomsen et al. (2008).^bThomsen et al. (2013).

can mediate a moderating effect on reward pathways, at least in rats. Although it is speculative, this notion of D₃ systems as performing a “dampening,” modulatory function is consistent with both PD-128,907 and PG01037 decreasing intracranial self-stimulation acutely in rats (Lazenka et al., 2016).

Chronic administration of a D₂ receptor agonist (NPA) or antagonist (L741,626) also produced effects in agreement with previous studies in monkeys. For example, in agreement with our study, chronic 5-day treatment with NPA in rhesus monkeys initially shifted the cocaine self-administration curve to the left and down and decreased cocaine intake, but tolerance developed after 5-day administration, at least in subordinate monkeys (Czoty and Nader, 2013). NPA also produced some cocaine-lever choice during the first component, both acutely and after continuous administration, when no cocaine was available. This is consistent with acute effects of D₂-family receptor agonists in rats and monkeys under similar conditions, as well as with NPA functioning as a positive reinforcer in monkeys (Weissenborn et al., 1996; Barrett et al., 2004; Gasior et al., 2004; Rowlett et al., 2007). Consistent with our findings using L741,626, chronic L741,626 or eticlopride suppressed food- and cocaine-reinforced responding nonselectively in monkeys (Clayton et al., 2006; Achat-Mendes et al., 2010). Despite an initial decrease in cocaine choice with one dose of L741,626 in this study, both NPA and L741,626, if anything, increased percent cocaine choice after continuous administration and neither decreased total cocaine intake.

Chronic administration of a D₃ receptor agonist (PF-592,379) or antagonist (PG01037) also produced effects distinct from the D₂ ligands. Acutely, PF-592,379 moderately decreased food choices with no effect on cocaine, but chronic PF-592,379 increased self-administration of low doses of cocaine while further decreasing food choices. This undesirable profile is in agreement with the effects of a D₃-preferring partial agonist in monkeys, and of 15-day treatment with pramipexole, which strongly increased positive subjective effects of cocaine in humans (Achat-Mendes et al., 2009; Newton et al., 2015). Unlike NPA, PF-592,379 produced little responding on the cocaine-associated lever during the first component, consistent with the notion that D₃-preferring agonists can enhance the conditioned reinforcing effects of cocaine-associated cues but maintain little responding per se (Collins and Woods, 2009; Collins et al., 2012). Consistent with

the acute dosing data and with previous single-reinforcer studies in monkeys, PG01037 had minimal effects on cocaine self-administration up to doses that also suppressed food-reinforced responding (Achat-Mendes et al., 2010). However, consistent with choice studies in monkeys, 3.2 mg/kg PG01037 produced a significant downward shift in the cocaine curve, with tolerance after continuous administration (Czoty and Nader, 2015; John et al., 2015a). A higher dose suppressed responding nonselectively. Although effects on food did not reach statistical significance, it is perhaps worth noting that PG01037 was the only treatment that increased food intake after chronic administration in our studies, whereas L741,626 mostly decreased food-reinforced responding. This is consistent with recent studies using dopamine receptor knockout mice, which indicated that D₂, rather D₃ or D₄, receptors mediate reinforcing effects of food (Soto et al., 2016).

In terms of total cocaine intake and overall food-reinforced behavior, none of the treatment regimens offered promising medication-like profiles in this assay. Up to doses that disrupted food-reinforced behavior, no compound decreased cocaine intake significantly. Similarly, the 5-HT_{1A} agonist and D₃/D₄ antagonist buspirone reduced cocaine self-administration in monkeys acutely, but it increased cocaine choice after 5-day treatment and failed to improve time to relapse or cocaine taking in clinical trials (Bergman et al., 2013; Winhusen et al., 2014; John et al., 2015b; Bolin et al., 2016; but see Mello et al., 2013). In fact, buspirone increased cocaine use in women (Winhusen et al., 2014). One possible reason for the variable and typically modest effects of PG01037 and other D₃ receptor antagonists may be highly variable sensitivity between individuals, which was observed here and in monkeys (Czoty and Nader, 2015; John et al., 2015a). For all compounds tested, the effects of high doses on food-reinforced behavior persisted or increased during chronic administration. Although blood drug levels were not measured, it is likely that some or all ligands were tested up to doses that produced moderate drug accumulation, although the development of sensitization rather than tolerance is also possible. Drug accumulation is most likely to have occurred for L-741,626 and PF-592,379 based on pilot pharmacokinetic studies (PF-592,379) and the observation that rats typically required at least 3 days to re-establish baseline levels of responding after minipump removal with those ligands. Regardless of mechanism, the dissociation of chronic effects on

cocaine and food indicates that distinct pharmacological mechanisms underlie effects on cocaine and nondrug reinforcement. Unfortunately, this profile may suggest that dose-limiting, undesirable effects of dopamine receptor ligands in humans may also be resistant to tolerance.

In conclusion, the cocaine versus food choice procedure in rats produced data consistent with studies in monkeys and human subjects. Furthermore, these findings underline the importance of testing chronic or subchronic administration of compounds of interest at the preclinical stage. In particular, both the D₂ antagonist L-741,626 and the D₃ antagonist PG01037 decreased cocaine choice at some dose as acute treatment, but after 1 week, neither drug significantly altered cocaine choice. Here, access to cocaine was not suspended during treatments, and it is possible that effects of chronic D₃ receptor antagonism could be larger if tested under suspended access conditions (Czoty and Nader, 2013). However, the difficulty in establishing abstinence in cocaine-dependent patients means that candidate medications should also be evaluated under conditions of continued cocaine access during treatment (Moran et al., 2017). Other factors that may influence the effectiveness of dopamine receptor ligands include feeding conditions, age, sex, and social status (Czoty and Nader, 2013, 2015; Baladi et al., 2014; Collins et al., 2014; Jupp et al., 2016), and our data may not generalize to smaller/leaner subjects, females, and so forth. It would be of interest to examine cocaine self-administration behaviors of rats living in social groups, where access to social interactions, mating, and so forth would arguably function as competing reinforcers.

Acknowledgments

The authors thank Drs. Amy Newman and Peter Grundt (National Institutes of Health National Institute on Drug Abuse, Intramural Research Program) for providing PG01037 for this study. They also thank Drs. István Gyertyán and Krisztina Gál and Richter Gedeon Ltd. for providing RGH-237 for this study. Finally, they thank John Miller, Dana Angood, and Justin Hamilton for expert technical assistance.

Authorship Contributions

Participated in research design: Barrett, Negus, Caine.

Conducted experiments: Barrett, Caine.

Contributed new reagents or analytic tools: Butler.

Performed data analysis: Thomsen.

Wrote or contributed to the writing of the manuscript: Thomsen, Barrett, Butler, Negus, Caine.

References

- Achat-Mendes C, Grundt P, Cao J, Platt DM, Newman AH, and Spealman RD (2010) Dopamine D3 and D2 receptor mechanisms in the abuse-related behavioral effects of cocaine: studies with preferential antagonists in squirrel monkeys. *J Pharmacol Exp Ther* **334**:556–565.
- Achat-Mendes C, Platt DM, Newman AH, and Spealman RD (2009) The dopamine D3 receptor partial agonist CJB 090 inhibits the discriminative stimulus but not the reinforcing or priming effects of cocaine in squirrel monkeys. *Psychopharmacology (Berl)* **206**:73–84.
- Attkins N, Betts A, Hepworth D, and Heatherington AC (2010) Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human. *Xenobiotica* **40**:730–742.
- Baladi MG, Newman AH, and France CP (2014) Feeding condition and the relative contribution of different dopamine receptor subtypes to the discriminative stimulus effects of cocaine in rats. *Psychopharmacology (Berl)* **231**:581–591.
- Banks ML, Blough BE, Fennell TR, Snyder RW, and Negus SS (2013) Effects of phendimetrazine treatment on cocaine vs food choice and extended-access cocaine consumption in rhesus monkeys. *Neuropsychopharmacology* **38**:2698–2707.
- Banks ML, Blough BE, and Negus SS (2011) Effects of monoamine releasers with varying selectivity for releasing dopamine/norepinephrine versus serotonin on choice between cocaine and food in rhesus monkeys. *Behav Pharmacol* **22**:824–836.
- Banks ML, Hutsell BA, Blough BE, Poklis JL, and Negus SS (2015b) Preclinical assessment of lisdexamfetamine as an agonist medication candidate for cocaine addiction: effects in rhesus monkeys trained to discriminate cocaine or to self-administer cocaine in a cocaine versus food choice procedure. *Int J Neuropsychopharmacol* **18**:18.
- Banks ML, Hutsell BA, Schwientek KL, and Negus SS (2015a) Use of preclinical drug vs. food choice procedures to evaluate candidate medications for cocaine addiction. *Curr Treat Options Psychiatry* **2**:136–150.
- Banks ML and Negus SS (2017) Insights from preclinical choice models on treating drug addiction. *Trends Pharmacol Sci* **38**:181–194.
- Barrett AC, Miller JR, Dohrmann JM, and Caine SB (2004) Effects of dopamine indirect agonists and selective D1-like and D2-like agonists and antagonists on cocaine self-administration and food maintained responding in rats. *Neuropharmacology* **47** (Suppl 1):256–273.
- Beardsley PM, Sokoloff P, Balster RL, and Schwartz JC (2001) The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered. *Behav Pharmacol* **12**:1–11.
- Bergman J (2008) Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D-sub-2 partial agonist aripiprazole (Ablify). *Exp Clin Psychopharmacol* **16**:475–483.
- Bergman J, Kamien JB, and Spealman RD (1990) Antagonism of cocaine self-administration by selective dopamine D(1) and D(2) antagonists. *Behav Pharmacol* **1**:355–363.
- Bergman J, Roof RA, Furman CA, Conroy JL, Mello NK, Sibley DR, and Skolnick P (2013) Modification of cocaine self-administration by buspirone (Buspar®): potential involvement of D3 and D4 dopamine receptors. *Int J Neuropsychopharmacol* **16**:445–458.
- Boileau I, Payer D, Houle S, Behzadi A, Rusjan PM, Tong J, Wilkins D, Selby P, George TP, Zack M, et al. (2012) Higher binding of the dopamine D3 receptor-prefering ligand [¹¹C](+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. *J Neurosci* **32**:1353–1359.
- Bolin BL, Lile JA, Marks KR, Beckmann JS, Rush CR, and Stoops WW (2016) Buspirone reduces sexual risk-taking intent but not cocaine self-administration. *Exp Clin Psychopharmacol* **24**:162–173.
- Caine SB, Negus SS, and Mello NK (2000) Effects of dopamine D(1-like) and D(2-like) agonists on cocaine self-administration in rhesus monkeys: rapid assessment of cocaine dose-effect functions. *Psychopharmacology (Berl)* **148**:41–51.
- Caine SB, Negus SS, Mello NK, and Bergman J (1999) Effects of dopamine D(1-like) and D(2-like) agonists in rats that self-administer cocaine. *J Pharmacol Exp Ther* **291**:353–360.
- Caine SB, Negus SS, Mello NK, Patel S, Bristow L, Kulagowski J, Vallone D, Saiardi A, and Borrelli E (2002) Role of dopamine D2-like receptors in cocaine self-administration: studies with D2 receptor mutant mice and novel D2 receptor antagonists. *J Neurosci* **22**:2977–2988.
- Caine SB, Thomsen M, Barrett AC, Collins GT, Grundt P, Newman AH, Butler P, and Xu M (2012) Cocaine self-administration in dopamine D₃ receptor knockout mice. *Exp Clin Psychopharmacol* **20**:352–363.
- Chiodo KA, Läck CM, and Roberts DC (2008) Cocaine self-administration reinforced on a progressive ratio schedule decreases with continuous D-amphetamine treatment in rats. *Psychopharmacology (Berl)* **200**:465–473.
- Clayton R, Lile JA, and Nader MA (2006) The effects of eticlopride and the selective D3-antagonist PNU 99194-A on food- and cocaine-maintained responding in rhesus monkeys. *Pharmacol Biochem Behav* **83**:456–464.
- Collins GT, Butler P, Wayman C, Ratcliffe S, Gupta P, Oberhofer G, and Caine SB (2012) Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats. *Behav Pharmacol* **23**:280–291.
- Collins GT, Jackson JA, Koek W, and France CP (2014) Effects of dopamine D(2)-like receptor agonists in mice trained to discriminate cocaine from saline: influence of feeding condition. *Eur J Pharmacol* **729**:123–131.
- Collins GT, Truong YN, Levant B, Chen J, Wang S, and Woods JH (2011) Behavioral sensitization to cocaine in rats: evidence for temporal differences in dopamine D3 and D2 receptor sensitivity. *Psychopharmacology (Berl)* **215**:609–620.
- Collins GT and Woods JH (2009) Influence of conditioned reinforcement on the response-maintaining effects of quinpirole in rats. *Behav Pharmacol* **20**:492–504.
- Comer SD, Ashworth JB, Foltin RW, Johanson CE, Zacny JP, and Walsh SL (2008) The role of human drug self-administration procedures in the development of medications. *Drug Alcohol Depend* **96**:1–15.
- Czoty PW, Gould RW, Martelle JL, and Nader MA (2011) Prolonged attenuation of the reinforcing strength of cocaine by chronic d-amphetamine in rhesus monkeys. *Neuropsychopharmacology* **36**:539–547.
- Czoty PW, Martelle JL, and Nader MA (2010) Effects of chronic d-amphetamine administration on the reinforcing strength of cocaine in rhesus monkeys. *Psychopharmacology (Berl)* **209**:375–382.
- Czoty PW and Nader MA (2013) Effects of dopamine D2/D3 receptor ligands on food-cocaine choice in socially housed male cynomolgus monkeys. *J Pharmacol Exp Ther* **344**:329–338.
- Czoty PW and Nader MA (2015) Effects of oral and intravenous administration of buspirone on food-cocaine choice in socially housed male cynomolgus monkeys. *Neuropsychopharmacology* **40**:1072–1083.
- Czoty PW, Stoops WW, and Rush CR (2016) Evaluation of the “pipeline” for development of medications for cocaine use disorder: a review of translational preclinical, human laboratory, and clinical trial research. *Pharmacol Rev* **68**:533–562.
- Foltin RW, Haney M, Rubin E, Reed SC, Vadhan N, Balter R, and Evans SM (2015) Development of translational preclinical models in substance abuse: effects of cocaine administration on cocaine choice in humans and non-human primates. *Pharmacol Biochem Behav* **134**:12–21.

- Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, and McAllister G (1994) Expression and pharmacological characterization of the human D3 dopamine receptor. *J Pharmacol Exp Ther* **268**:417–426.
- Gál K and Gyertyán I (2003) Targeting the dopamine D3 receptor cannot influence continuous reinforcement cocaine self-administration in rats. *Brain Res Bull* **61**: 595–601.
- Gasior M, Paronis CA, and Bergman J (2004) Modification by dopaminergic drugs of choice behavior under concurrent schedules of intravenous saline and food delivery in monkeys. *J Pharmacol Exp Ther* **308**:249–259.
- Grabowski J, Rhoades H, Schmitz J, Stotts A, Daruzska LA, Creson D, and Moeller FG (2001) Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. *J Clin Psychopharmacol* **21**:522–526.
- Grabowski J, Rhoades H, Silverman P, Schmitz JM, Stotts A, Creson D, and Bailey R (2000) Risperidone for the treatment of cocaine dependence: randomized, double-blind trial. *J Clin Psychopharmacol* **20**:305–310.
- Greenwald MK, Lundahl LH, and Steinmiller CL (2010) Sustained release d-amphetamine reduces cocaine but not 'speedball'-seeking in buprenorphine-maintained volunteers: a test of dual-agonist pharmacotherapy for cocaine/heroin polydrug abusers. *Neuropsychopharmacology* **35**:2624–2637.
- Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, and Newman AH (2005) Novel heterocyclic trans olefin analogues of N-4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butylarylcaboxamides as selective probes with high affinity for the dopamine D3 receptor. *J Med Chem* **48**:839–848.
- Gyertyán I, Kiss B, Gál K, Laszlovsky I, Horváth A, Gémesi LI, Sággy K, Pásztor G, Zájér M, Kapás M, et al. (2007) Effects of RGH-237 [N-4-[4-(3-aminocarbonyl-phenyl)-piperazin-1-yl]-butyl-4-bromo-benzamide], an orally active, selective dopamine D(3) receptor partial agonist in animal models of cocaine abuse. *J Pharmacol Exp Ther* **320**:1268–1278.
- Haile CN and Kosten TA (2001) Differential effects of D1- and D2-like compounds on cocaine self-administration in Lewis and Fischer 344 inbred rats. *J Pharmacol Exp Ther* **299**:509–518.
- Haney M, Rubin E, and Foltin RW (2011) Aripiprazole maintenance increases smoked cocaine self-administration in humans. *Psychopharmacology (Berl)* **216**: 379–387.
- Haney M and Spealman R (2008) Controversies in translational research: drug self-administration. *Psychopharmacology (Berl)* **199**:403–419.
- Haney M, Ward AS, Foltin RW, and Fischman MW (2001) Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans. *Psychopharmacology (Berl)* **155**:330–337.
- Heidbreder CA and Newman AH (2010) Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders. *Ann N Y Acad Sci* **1187**:4–34.
- Hutsell BA, Negus SS, and Banks ML (2016) Effects of 21-day d-amphetamine and risperidone treatment on cocaine vs food choice and extended-access cocaine intake in male rhesus monkeys. *Drug Alcohol Depend* **168**:36–44.
- John WS, Banala AK, Newman AH, and Nader MA (2015b) Effects of buspirone and the dopamine D3 receptor compound PG619 on cocaine and methamphetamine self-administration in rhesus monkeys using a food-drug choice paradigm. *Psychopharmacology (Berl)* **232**:1279–1289.
- John WS, Newman AH, and Nader MA (2015a) Differential effects of the dopamine D3 receptor antagonist PG01037 on cocaine and methamphetamine self-administration in rhesus monkeys. *Neuropsychopharmacology* **92**:34–43.
- Johnson AR, Banks ML, Blough BE, Lile JA, Nicholson KL, and Negus SS (2016) Development of a translational model to screen medications for cocaine use disorder I: choice between cocaine and food in rhesus monkeys. *Drug Alcohol Depend* **165**:103–110.
- Jupp B, Murray JE, Jordan ER, Xia J, Fluaharty M, Shrestha S, Robbins TW, and Dalley JW (2016) Social dominance in rats: effects on cocaine self-administration, novelty reactivity and dopamine receptor binding and content in the striatum. *Psychopharmacology (Berl)* **233**:579–589.
- Keck TM, John WS, Czoty PW, Nader MA, and Newman AH (2015) Identifying medication targets for psychostimulant addiction: unraveling the dopamine D3 receptor hypothesis. *J Med Chem* **58**:5361–5380.
- Kishi T, Matsuda Y, Iwata N, and Correll CU (2013) Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials. *J Clin Psychiatry* **74**:e1169–e1180.
- Kleven MS and Woolverton WL (1990) Effects of continuous infusions of SCH 23390 on cocaine- or food-maintained behavior in rhesus monkeys. *Behav Pharmacol* **1**:365–373.
- Kulagowski JJ, Broughton HB, Curtis NR, Mawer IM, Ridgill MP, Baker R, Emms F, Freedman SB, Marwood R, Patel S, et al. (1996) 3-((4-(4-chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor. *J Med Chem* **39**:1941–1942.
- Lazenka MF, Legakis LP, and Negus SS (2016) Opposing effects of dopamine D1- and D2-like agonists on intracranial self-stimulation in male rats. *Exp Clin Psychopharmacol* **24**:193–205.
- Le Foll B, Francès H, Diaz J, Schwartz JC, and Sokoloff P (2002) Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. *Eur J Neurosci* **15**:2016–2026.
- Lile JA, Stoops WW, Rush CR, Negus SS, Glaser PE, Hatton KW, and Hays LR (2016) Development of a translational model to screen medications for cocaine use disorder II: Choice between intravenous cocaine and money in humans. *Drug Alcohol Depend* **165**:111–119.
- Loeb T, Angarita GA, Pachas GN, Huang KL, Lee SH, Nino J, Logvinenko T, Culhane MA, and Evins AE (2008) A randomized, double-blind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men. *J Clin Psychiatry* **69**: 480–486.
- Lofwall MR, Nuzzo PA, Campbell C, and Walsh SL (2014) Aripiprazole effects on self-administration and pharmacodynamics of intravenous cocaine and cigarette smoking in humans. *Exp Clin Psychopharmacol* **22**:238–247.
- Mason CW, Hassan HE, Kim KP, Cao J, Eddington ND, Newman AH, and Voulalas PJ (2010) Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse. *J Pharmacol Exp Ther* **333**: 854–864.
- Meador-Woodruff JH, Little KY, Damask SP, and Watson SJ (1995) Effects of cocaine on D3 and D4 receptor expression in the human striatum. *Biol Psychiatry* **38**: 263–266.
- Mello NK, Fivel PA, Kohut SJ, and Bergman J (2013) Effects of chronic buspirone treatment on cocaine self-administration. *Neuropsychopharmacology* **38**: 455–467.
- Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM, Audinot V, Dubuffet T, and Lavielle G (2000) S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. *J Pharmacol Exp Ther* **293**:1048–1062.
- Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, and Newman-Tancredi A (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. *J Pharmacol Exp Ther* **303**: 791–804.
- Minozzi S, Amato L, Pani PP, Solimini R, Vecchi S, De Crescenzo F, Zuccaro P, and Davoli M (2015) Dopamine agonists for the treatment of cocaine dependence. *Cochrane Database Syst Rev* (5):CD003352.
- Mooney ME, Herin DV, Schmitz JM, Moukaddam N, Green CE, and Grabowski J (2009) Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. *Drug Alcohol Depend* **101**:34–41.
- Moran LM, Phillips KA, Kowalczyk WJ, Ghitza UE, Agage DA, Epstein DH, and Preston KL (2017) Aripiprazole for cocaine abstinence: a randomized-controlled trial with ecological momentary assessment. *Behav Pharmacol* **28**: 63–73.
- Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, and Street SD (2012) Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. *Drug Discov Today* **17**:419–424.
- Nader MA, Morgan D, Gage HD, Nader SH, Calhoun TL, Buchheimer N, Ehrenkauffer R, and Mach RH (2006) PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. *Nat Neurosci* **9**:1050–1056.
- Nann-Vernotica E, Donny EC, Bigelow GE, and Walsh SL (2001) Repeated administration of the D1/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine. *Psychopharmacology (Berl)* **155**:338–347.
- Negus SS (2003) Rapid assessment of choice between cocaine and food in rhesus monkeys: effects of environmental manipulations and treatment with d-amphetamine and flupenthixol. *Neuropsychopharmacology* **28**:919–931.
- Negus SS and Henningfield J (2015) Agonist medications for the treatment of cocaine use disorder. *Neuropsychopharmacology* **40**:1815–1825.
- Negus SS and Mello NK (2003) Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a progressive-ratio schedule in rhesus monkeys. *Psychopharmacology (Berl)* **167**:324–332.
- Negus SS, Mello NK, Lamas X, and Mendelson JH (1996) Acute and chronic effects of flupenthixol on the discriminative stimulus and reinforcing effects of cocaine in rhesus monkeys. *J Pharmacol Exp Ther* **278**:879–890.
- Neisewander JL, Fuchs RA, Tran-Nguyen LT, Weber SM, Coffey GP, and Joyce JN (2004) Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine-seeking behavior. *Neuropsychopharmacology* **29**:1479–1487.
- Newton TF, Haile CN, Mahoney JJ, 3rd, Shah R, Verrico CD, De La Garza R, 2nd, and Kosten TR (2015) Dopamine D3 receptor-preferring agonist enhances the subjective effects of cocaine in humans. *Psychiatry Res* **230**:44–49.
- Nuijten M, Blanken P, van de Wetering B, Nuijten B, van den Brink W, and Hendriks VM (2016) Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial. *Lancet* **387**:2226–2234.
- O'Connor PG, Sokol RJ, and D'Onofrio G (2014) Addiction medicine: the birth of a new discipline. *JAMA Intern Med* **174**:1717–1718.
- Pérez-Mañá C, Castells X, Vidal X, Casas M, and Capellà D (2011) Efficacy of indirect dopamine agonists for psychostimulant dependence: a systematic review and meta-analysis of randomized controlled trials. *J Subst Abuse Treat* **40**:109–122.
- Pugsley TA, Davis MD, Akunne HC, MacKenzie RG, Shih YH, Damsa G, Wikstrom H, Whetzel SZ, Georgic LM, Cooke LW, et al. (1995) Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. *J Pharmacol Exp Ther* **275**:1355–1366.
- Romach MK, Glue P, Kampman K, Kaplan HL, Somer GR, Poole S, Clarke L, Coffin V, Cornish J, O'Brien CP, et al. (1999) Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166). *Arch Gen Psychiatry* **56**:1101–1106.
- Rowlett JK, Platt DM, Yao WD, and Spealman RD (2007) Modulation of heroin and cocaine self-administration by dopamine D1- and D2-like receptor agonists in rhesus monkeys. *J Pharmacol Exp Ther* **321**:1135–1143.
- Sautel F, Griffon N, Lévesque D, Pilon C, Schwartz JC, and Sokoloff P (1995) A functional test identifies dopamine agonists selective for D3 versus D2 receptors. *Neuroreport* **6**:329–332.
- Segal DM, Moraes CT, and Mash DC (1997) Up-regulation of D3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities. *Brain Res Mol Brain Res* **45**:335–339.
- Shearer J, Wodak A, van Beek I, Mattick RP, and Lewis J (2003) Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. *Addiction* **98**:1137–1141.
- Skolnick P (2015) Biologic approaches to treat substance-use disorders. *Trends Pharmacol Sci* **36**:628–635.

- Sokoloff P and Le Foll B (2017) The dopamine D3 receptor, a quarter century later. *Eur J Neurosci* **45**:2–19.
- Soto PL, Hiranita T, Xu M, Hursh SR, Grandy DK, and Katz JL (2016) Dopamine D₂-like receptors and behavioral economics of food reinforcement. *Neuropsychopharmacology* **41**:971–978.
- Staley JK and Mash DC (1996) Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. *J Neurosci* **16**:6100–6106.
- Stoops WW, Lile JA, Lofwall MR, and Rush CR (2007) The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance. *Am J Drug Alcohol Abuse* **33**:769–776.
- Thomsen M, Barrett AC, Negus SS, and Caine SB (2013) Cocaine versus food choice procedure in rats: environmental manipulations and effects of amphetamine. *J Exp Anal Behav* **99**:211–233.
- Thomsen M and Caine SB (2005) Chronic intravenous drug self-administration in rats and mice. *Curr Protoc Neurosci* Chapter **9**:Unit 9.20.
- Thomsen M, Fink-Jensen A, Woldbye DP, Wörtwein G, Sager TN, Holm R, Pepe LM, and Caine SB (2008) Effects of acute and chronic aripiprazole treatment on choice between cocaine self-administration and food under a concurrent schedule of reinforcement in rats. *Psychopharmacology (Berl)* **201**:43–53.
- Thomsen M, Fulton BS, and Caine SB (2014) Acute and chronic effects of the M1/M4-preferring muscarinic agonist xanomeline on cocaine vs. food choice in rats. *Psychopharmacology (Berl)* **231**:469–479.
- Weissenborn R, Deroche V, Koob GF, and Weiss F (1996) Effects of dopamine agonists and antagonists on cocaine-induced operant responding for a cocaine-associated stimulus. *Psychopharmacology (Berl)* **126**:311–322.
- Winhusen TM, Kropp F, Lindblad R, Douaihy A, Haynes L, Hodgkins C, Chartier K, Kampman KM, Sharma G, Lewis DF, et al. (2014) Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence. *J Clin Psychiatry* **75**:757–764.

Address correspondence to: Morgane Thomsen, Alcohol and Drug Abuse Research Center, McLean Hospital, Mail Stop 214, 115 Mill Street, Belmont, MA 02478. E-mail: mthomsen@mclean.harvard.edu